Clinical Trials Browser

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04803929 2021-03-23

Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)

Phase EARLY_PHASE1 Unknown

25 enrolled

Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myelomonocytic, Acute

NCT04700319 2021-03-08

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

Phase EARLY_PHASE1 Unknown

30 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT04439721 2021-01-06

γδT

Phase EARLY_PHASE1 Unknown

5 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell

NCT04626765 2020-11-13

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Phase EARLY_PHASE1 Unknown

50 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04209712 2020-07-29

Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease

Phase EARLY_PHASE1 Unknown

6 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04156178 2019-11-12

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

Phase EARLY_PHASE1 Unknown

12 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, B-Cell, Lymphoma, B-Cell

NCT04156243 2019-11-12

CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

Phase EARLY_PHASE1 Unknown

20 enrolled

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

NCT04156256 2019-11-12

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Phase EARLY_PHASE1 Unknown

20 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT03910842 2019-09-06

Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy

Phase EARLY_PHASE1 Unknown

12 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin

Clinical Trials

Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors

Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

γδ T Cell Therapy for Relapse Prevention in High-Risk AML Post-Transplant

Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia

iNK-r/r AML

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

Reboot-101

To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia

Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

γδT

CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy